ZA200400210B - Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases - Google Patents

Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Info

Publication number
ZA200400210B
ZA200400210B ZA2004/00210A ZA200400210A ZA200400210B ZA 200400210 B ZA200400210 B ZA 200400210B ZA 2004/00210 A ZA2004/00210 A ZA 2004/00210A ZA 200400210 A ZA200400210 A ZA 200400210A ZA 200400210 B ZA200400210 B ZA 200400210B
Authority
ZA
South Africa
Prior art keywords
compositions
treatment
methods
binding agents
ocular diseases
Prior art date
Application number
ZA2004/00210A
Other languages
English (en)
Inventor
Sherris David
Wood Mark
Original Assignee
Oxigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxigene Inc filed Critical Oxigene Inc
Publication of ZA200400210B publication Critical patent/ZA200400210B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA2004/00210A 2001-07-13 2004-01-12 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases ZA200400210B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38622701P 2001-07-13 2001-07-13
US37784502P 2002-05-03 2002-05-03
US37784702P 2002-05-03 2002-05-03
US37755602P 2002-05-03 2002-05-03
PCT/US2002/022449 WO2003006002A1 (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
ZA200400210B true ZA200400210B (en) 2005-06-29

Family

ID=32034390

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2004/00210A ZA200400210B (en) 2001-07-13 2004-01-12 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Country Status (8)

Country Link
EP (1) EP1406600A4 (enExample)
JP (2) JP2004536847A (enExample)
KR (1) KR20040030042A (enExample)
CN (1) CN1527704B (enExample)
CA (1) CA2453442C (enExample)
NZ (1) NZ575466A (enExample)
WO (1) WO2003006002A1 (enExample)
ZA (1) ZA200400210B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP4005048B2 (ja) * 2003-04-09 2007-11-07 日信工業株式会社 炭素繊維複合材料およびその製造方法
CA2766178A1 (en) * 2009-07-02 2011-01-06 Oxigene, Inc. Combretastatins for prevention of posterior capsule opacification
CN106822083A (zh) 2009-08-27 2017-06-13 生物学特性有限公司 用于治疗增生性疾病的联合疗法
JP2013502440A (ja) * 2009-08-27 2013-01-24 バイオノミックス リミテッド 黄斑変性の治療
SG11201500688XA (en) * 2012-08-02 2015-02-27 Amril Ag Natural rubber containing nanocarbon
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
DE69942645D1 (en) * 1998-01-09 2010-09-16 Body Corporate Of The State Of Synthese von combretastatin a-4 prodrugs
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
WO2003006002A9 (en) 2004-07-22
JP2004536847A (ja) 2004-12-09
CA2453442A1 (en) 2003-01-23
WO2003006002A8 (en) 2004-05-27
WO2003006002A1 (en) 2003-01-23
JP2009132738A (ja) 2009-06-18
CA2453442C (en) 2011-02-01
NZ575466A (en) 2011-01-28
CN1527704A (zh) 2004-09-08
EP1406600A1 (en) 2004-04-14
CN1527704B (zh) 2011-05-18
EP1406600A4 (en) 2007-06-06
KR20040030042A (ko) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
AU2002345255A1 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
IL176227A0 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
HUP0104963A3 (en) Compositions for the treatment of skin diseases
HU0002963D0 (en) Methods and compositions for treating diseases and conditions of the eye field of invention
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
EP1416795A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES OF MITOCHONDRIA
EP1425027A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF WOUNDS AND BURNS
EP1406600A4 (en) COMPOSITIONS AND METHOD FOR THE ADMINISTRATION OF TUBULIN BINDING AGENTS FOR THE TREATMENT OF EYE DISEASES
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1472273A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
AU2002366028A1 (en) Use of fk506 and analogues for treating allergic diseases
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
AU2002363228A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
HK1064941A (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
IL159581A0 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases